Continuing Medical Education Program - Purchase Activities
The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

  The Medical Letter Individual Activities — Online Only
I would like to order the following Per Issue Activities eligible for 2 credits each: $15/activity
3 or more: $10/activity
1590  (2 credits)   Expires 01/27/2021
Drugs for ADHD
1591  (2 credits)   Expires 02/10/2021
Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
Istradefylline (Nourianz) for Parkinson's Disease
Brolucizumab (Beovu) for Age-Related Macular Degeneration
1592  (2 credits)
Drugs for Depression
1593  (2 credits)
Peanut Allergen Powder (Palforzia)
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors
1594  (2 credits)
Drugs for Irritable Bowel Syndrome
1595  (2 credits)
Some Drugs for COVID-19
Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta)
Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol
Intravenous Cetirizine (Quzyttir) for Acute Urticaria
1596  (2 credits)
Drugs for Osteoarthritis
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Cluster
1597  (2 credits)
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
Minocycline Foam (Amzeeq) for Acne
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
1598  (2 credits)
Drugs for Hypertension
1599  (2 credits)
Respiratory Depression with Gabapentinoids
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
Talicia - A 3-Drug Combination for Helicobacter pylori Infection
Eptinezumab (Vyepti) for Migraine Prevention
Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes
1600  (2 credits)
Drugs for Atopic Dermatitis
1601  (2 credits)
Lemborexant (Dayvigo) for Insomnia
IV Meloxicam (Anjeso) for Pain
Dapagliflozin (Farxiga) - A New Indication for Heart Failure
Melatonin for Insomnia in Children
1602  (2 credits)
Drugs for Postmenopausal Osteoporosis
1603  (2 credits)
Lumateperone (Caplyta) for Schizophrenia
Durysta - A Bimatoprost Implant for Glaucoma
Drugs Past Their Expiration Date
Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy
1604  (2 credits)
IV Artesunate for Severe Malaria
Drugs for Menopausal Symptoms
1605  (2 credits)
Phexxi - A Nonhormonal Contraceptive Gel
Ozanimod (Zeposia) for Multiple Sclerosis
Cenobamate (Xcopri) for Focal Seizures
1606  (2 credits)
Drugs for COPD
1607  (2 credits)
Influenza Vaccine for 2020-2021
A New Indication for Esketamine Nasal Spray (Spravato)
Canagliflozin and Lower Limb Amputations
1608  (2 credits)
Drugs for Migraine
1609  (2 credits)
Timing of Remdesivir for COVID-19
Lyumjev - A New Insulin Lispro for Diabetes
Caplacizumab (Cablivi) for iTTP
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy
Two New Doses of Dulaglutide (Trulicity) for Diabetes
1610  (2 credits)
Antiviral Drugs for Influenza for 2020-2021
Large-Volume, Preservative-Free Albuterol Concentrate
New Benzodiazepine Warnings
New Warnings on NSAID Use in Pregnancy
Extended-Release Budesonide (Ortikos) for Crohn's Disease
1611  (2 credits)
Hydrochlorothiazide and Skin Cancer
Empagliflozin (Jardiance) for Heart Failure
Minocycline Foam (Zilxi) for Rosacea
Orphengesic Forte - An Old Analgesic Combination Returns
Two Drugs for Advanced HER2-Positive Breast Cancer
1612  (2 credits)
An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19
Remdesivir (Veklury) for COVID-19
Drugs for Acne
New Meningococcal Serogroup B Vaccination Guidelines
1613  (2 credits)
Drugs for Asthma
1614  (2 credits)
An EUA for Casirivimab and Imdevimab for COVID-19
An EUA for Baricitinib (Olumiant) for COVID-19
Ofatumumab (Kesimpta) for MS
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
1615  (2 credits)
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
An Asenapine Patch (Secuado) for Schizophrenia
1616  (2 credits)
FDA Authorizes Moderna COVID-19 Vaccine
Antibacterial Drugs for Community-Acquired Pneumonia
Semglee - A New Insulin Glargine for Diabetes
Encorafenib (Braftovi) for Metastatic Colorectal Cancer


ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This Continuing Medical Education (CME) activity was planned and produced in accordance with the ACCME Essentials and Policies.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

AAFP This Enduring Material activity, The Medical Letter Continuing Medical Education Program, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 01/01/2021. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 52.00 AAPA Category 1 CME credits. Approval is valid for one year from 01/01/2021. PAs should only claim credit commensurate with the extent of their participation.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hour(s) of knowledge-based continuing education credit (0.2 CEU).